WO2002085305A3 - Compositions et methodes pouvant induire la mort de cellules cancereuses - Google Patents

Compositions et methodes pouvant induire la mort de cellules cancereuses Download PDF

Info

Publication number
WO2002085305A3
WO2002085305A3 PCT/US2002/013092 US0213092W WO02085305A3 WO 2002085305 A3 WO2002085305 A3 WO 2002085305A3 US 0213092 W US0213092 W US 0213092W WO 02085305 A3 WO02085305 A3 WO 02085305A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
cell death
methods
cancer cell
inducing cancer
Prior art date
Application number
PCT/US2002/013092
Other languages
English (en)
Other versions
WO2002085305A2 (fr
Inventor
Steven F Dowdy
Sergei A Ezhevsky
Jay S Wadia
Original Assignee
Univ Washington
Steven F Dowdy
Sergei A Ezhevsky
Jay S Wadia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Steven F Dowdy, Sergei A Ezhevsky, Jay S Wadia filed Critical Univ Washington
Priority to AU2002259005A priority Critical patent/AU2002259005A1/en
Publication of WO2002085305A2 publication Critical patent/WO2002085305A2/fr
Publication of WO2002085305A3 publication Critical patent/WO2002085305A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des compositions et une méthode pouvant induire la mort de cellules, telles que des cellules tumorales. Des compositions de l'invention sont de nouvelles protéines hybrides qui comprennent au moins un domaine de transduction de protéines (PTD) et au moins une séquence d'acides aminés codée par un virus de l'anémie infectieuse du poulet (CAV). L'invention concerne en outre une large gamme d'applications importantes comprenant l'utilisation du 'projectile magique' indispensable pour tuer des cellules cancéreuses in vitro et in vivo.
PCT/US2002/013092 2001-04-24 2002-04-24 Compositions et methodes pouvant induire la mort de cellules cancereuses WO2002085305A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002259005A AU2002259005A1 (en) 2001-04-24 2002-04-24 Compositions and methods for inducing cancer cell death

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28609901P 2001-04-24 2001-04-24
US60/286,099 2001-04-24

Publications (2)

Publication Number Publication Date
WO2002085305A2 WO2002085305A2 (fr) 2002-10-31
WO2002085305A3 true WO2002085305A3 (fr) 2003-12-18

Family

ID=23097063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/013092 WO2002085305A2 (fr) 2001-04-24 2002-04-24 Compositions et methodes pouvant induire la mort de cellules cancereuses

Country Status (2)

Country Link
AU (1) AU2002259005A1 (fr)
WO (1) WO2002085305A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1377667B1 (fr) * 2001-03-30 2008-11-19 Leadd B.V. Proteines de fusion pour le traitement specifique du cancer et de maladies auto-immunes
WO2005084158A2 (fr) * 2003-06-20 2005-09-15 The Regents Of The University Of California Transduction polypeptidique et peptides fusogenes
CA2605931A1 (fr) * 2005-04-26 2006-11-02 Karyon-Ctt Ltd Agents diagnostiques et therapeutiques
CN101081871A (zh) * 2006-05-31 2007-12-05 华中科技大学 蛋白转导域4－凋亡素融合蛋白(PTD4－Apoptin)及其制法和应用
CN101747437B (zh) * 2008-12-10 2012-09-26 浙江日升昌药业有限公司 凋亡素-ec-sod羧基末端蛋白转导域融合蛋白

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041191A1 (fr) * 1995-06-07 1996-12-19 Aesculaap B.V. Procedes et utilisations d'apoptosine
EP1188832A1 (fr) * 2000-09-08 2002-03-20 Leadd B.V. Méthode pour délivrer l'activité de l'apotin induisant l'apoptose spécifiquement au niveau d'une tumeur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041191A1 (fr) * 1995-06-07 1996-12-19 Aesculaap B.V. Procedes et utilisations d'apoptosine
EP1188832A1 (fr) * 2000-09-08 2002-03-20 Leadd B.V. Méthode pour délivrer l'activité de l'apotin induisant l'apoptose spécifiquement au niveau d'une tumeur

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HO A. ET AL.: "Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo", CAN. RES., vol. 61, 15 January 2001 (2001-01-15), pages 474 - 477, XP002179150 *
SCHWARZE S.R. ET AL.: "In vivo protein transduction: delivery of a biologically active protein into the mouse", SCIENCE, vol. 285, 3 September 1999 (1999-09-03), pages 1569 - 1572, XP002927988 *

Also Published As

Publication number Publication date
AU2002259005A1 (en) 2002-11-05
WO2002085305A2 (fr) 2002-10-31

Similar Documents

Publication Publication Date Title
WO2002020767A3 (fr) Composition d'analogue du g-csf et procede associe
WO2002085923A3 (fr) Incorporation in vivo d'acides amines non naturels
WO2005003296A3 (fr) Proteines hybrides d'albumine
WO2003020756A3 (fr) Expression hybride et en tandem de proteines de neisseria
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
EP2298355A3 (fr) Protéines de fusion d'albumine
TW428026B (en) Bifunctional protein, preparation and use
MXPA03002218A (es) Peptidos antimicrobianos y metodos de uso.
DE60238472D1 (de) Abschwächung der immunogenizität von fusionsproteinen
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
WO2004047728A3 (fr) Compositions et procedes destines au traitement de maladies de nature immune
ZA200200789B (en) Multiple cytokine-antibody complexes.
WO2005016962A3 (fr) Compositions et techniques de traitement de maladies liees a l'immunite
WO2000053758A3 (fr) Compositions et methodes de traitement des maladies immunitaires
WO1996034107A3 (fr) Proteines antivirales, sequences d'adn codant pour ces proteines et utilisations
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
WO2000073452A3 (fr) Compositions et methodes de traitement de maladies liees a l'immunite
AU2003231471A1 (en) Antimicrobial polypeptide and utizliation thereof
WO1999045098A3 (fr) Apport de proteines a des cellules eucaryotes au moyen de la yersinia recombinee
WO1995011977A3 (fr) Nouvelle proteine inactivant les ribosomes isolee a partir de la plante bryonia dioica
DE69900756D1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
WO2002062304A3 (fr) Agents cosmetiques et/ou pharmaceutiques
WO2002085305A3 (fr) Compositions et methodes pouvant induire la mort de cellules cancereuses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP